Reduced toxicity and enhanced antitumor efficacy of plumbagin using poly (lactic-co-glycolic) biodegradable injectable implant

U. V. Singh, K. S. Bisht, S. Rao, P. Uma Devi, N. Udupa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To prepare poly (lactic-co-glycolic) acid (PLGA) injectable gel implant for the delivery of plumbagin (PLB) to reduce the toxicity and enhance the antitumour efficacy. Method: PLGA was dissolved in triacetin and PLB was dissolved in this. A gel matrix was formed immediately on contact with aqueous fluid. In vitro release studies were carried out in phosphate buffered saline pH 7.4. Acute toxicity studies were performed in normal BALB/c mice and antitumour efficacy in BALB/c mice bearing Sarcoma-180 tumour. LD50 and volume doubling time (VDT) values for plain PLB and gel implant injection was found after subcutaneous injection. Results: In vitro release of PLB was observed for a week. It was dependent on the concentration of PLGA used. The LD50 for plain PLB and gel implant was found to be 8.60 mg/kg and 9.33 mg/kg. VDT for plain PLB and gel implant was found to be 6.5±0.9 days and 11.5±0.5 days respectively. Conclusion: The toxicity of PLB was reduced in mice after subcutaneous injection of the gel containing PLB compared to plain PLB. The VDT was significantly higher for the gel compared to plain PLB. Thus the gel implant could be an effective drug delivery system for reducing toxicity and enhancing the therapeutic efficacy of PLB.

Original languageEnglish
Pages (from-to)168-172
Number of pages5
JournalIndian Journal of Pharmacology
Volume29
Issue number3
Publication statusPublished - 06-1997

Fingerprint

Absorbable Implants
Milk
Injections
Gels
Lethal Dose 50
Subcutaneous Injections
Triacetin
plumbagin
Sarcoma 180
Drug Delivery Systems

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{e68da1178d2c4fbba8ed097383922f38,
title = "Reduced toxicity and enhanced antitumor efficacy of plumbagin using poly (lactic-co-glycolic) biodegradable injectable implant",
abstract = "Objective: To prepare poly (lactic-co-glycolic) acid (PLGA) injectable gel implant for the delivery of plumbagin (PLB) to reduce the toxicity and enhance the antitumour efficacy. Method: PLGA was dissolved in triacetin and PLB was dissolved in this. A gel matrix was formed immediately on contact with aqueous fluid. In vitro release studies were carried out in phosphate buffered saline pH 7.4. Acute toxicity studies were performed in normal BALB/c mice and antitumour efficacy in BALB/c mice bearing Sarcoma-180 tumour. LD50 and volume doubling time (VDT) values for plain PLB and gel implant injection was found after subcutaneous injection. Results: In vitro release of PLB was observed for a week. It was dependent on the concentration of PLGA used. The LD50 for plain PLB and gel implant was found to be 8.60 mg/kg and 9.33 mg/kg. VDT for plain PLB and gel implant was found to be 6.5±0.9 days and 11.5±0.5 days respectively. Conclusion: The toxicity of PLB was reduced in mice after subcutaneous injection of the gel containing PLB compared to plain PLB. The VDT was significantly higher for the gel compared to plain PLB. Thus the gel implant could be an effective drug delivery system for reducing toxicity and enhancing the therapeutic efficacy of PLB.",
author = "Singh, {U. V.} and Bisht, {K. S.} and S. Rao and {Uma Devi}, P. and N. Udupa",
year = "1997",
month = "6",
language = "English",
volume = "29",
pages = "168--172",
journal = "Indian Journal of Pharmacology",
issn = "0253-7613",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

Reduced toxicity and enhanced antitumor efficacy of plumbagin using poly (lactic-co-glycolic) biodegradable injectable implant. / Singh, U. V.; Bisht, K. S.; Rao, S.; Uma Devi, P.; Udupa, N.

In: Indian Journal of Pharmacology, Vol. 29, No. 3, 06.1997, p. 168-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reduced toxicity and enhanced antitumor efficacy of plumbagin using poly (lactic-co-glycolic) biodegradable injectable implant

AU - Singh, U. V.

AU - Bisht, K. S.

AU - Rao, S.

AU - Uma Devi, P.

AU - Udupa, N.

PY - 1997/6

Y1 - 1997/6

N2 - Objective: To prepare poly (lactic-co-glycolic) acid (PLGA) injectable gel implant for the delivery of plumbagin (PLB) to reduce the toxicity and enhance the antitumour efficacy. Method: PLGA was dissolved in triacetin and PLB was dissolved in this. A gel matrix was formed immediately on contact with aqueous fluid. In vitro release studies were carried out in phosphate buffered saline pH 7.4. Acute toxicity studies were performed in normal BALB/c mice and antitumour efficacy in BALB/c mice bearing Sarcoma-180 tumour. LD50 and volume doubling time (VDT) values for plain PLB and gel implant injection was found after subcutaneous injection. Results: In vitro release of PLB was observed for a week. It was dependent on the concentration of PLGA used. The LD50 for plain PLB and gel implant was found to be 8.60 mg/kg and 9.33 mg/kg. VDT for plain PLB and gel implant was found to be 6.5±0.9 days and 11.5±0.5 days respectively. Conclusion: The toxicity of PLB was reduced in mice after subcutaneous injection of the gel containing PLB compared to plain PLB. The VDT was significantly higher for the gel compared to plain PLB. Thus the gel implant could be an effective drug delivery system for reducing toxicity and enhancing the therapeutic efficacy of PLB.

AB - Objective: To prepare poly (lactic-co-glycolic) acid (PLGA) injectable gel implant for the delivery of plumbagin (PLB) to reduce the toxicity and enhance the antitumour efficacy. Method: PLGA was dissolved in triacetin and PLB was dissolved in this. A gel matrix was formed immediately on contact with aqueous fluid. In vitro release studies were carried out in phosphate buffered saline pH 7.4. Acute toxicity studies were performed in normal BALB/c mice and antitumour efficacy in BALB/c mice bearing Sarcoma-180 tumour. LD50 and volume doubling time (VDT) values for plain PLB and gel implant injection was found after subcutaneous injection. Results: In vitro release of PLB was observed for a week. It was dependent on the concentration of PLGA used. The LD50 for plain PLB and gel implant was found to be 8.60 mg/kg and 9.33 mg/kg. VDT for plain PLB and gel implant was found to be 6.5±0.9 days and 11.5±0.5 days respectively. Conclusion: The toxicity of PLB was reduced in mice after subcutaneous injection of the gel containing PLB compared to plain PLB. The VDT was significantly higher for the gel compared to plain PLB. Thus the gel implant could be an effective drug delivery system for reducing toxicity and enhancing the therapeutic efficacy of PLB.

UR - http://www.scopus.com/inward/record.url?scp=0030851428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030851428&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030851428

VL - 29

SP - 168

EP - 172

JO - Indian Journal of Pharmacology

JF - Indian Journal of Pharmacology

SN - 0253-7613

IS - 3

ER -